Incentivising the Development of New Antibacterial Treatments 2024: Progress Report by the Global AMR R&D Hub and WHO

Incentivising the Development of New Antibacterial Treatments 2024: Progress Report by the Global AMR R&D Hub and WHO

Since 2021, G7 Finance and Health Ministers have reinforced their commitment to accelerating antimicrobial resistance (AMR) strategies, addressing the antibiotic pipeline and market failure, preserving access to essential antibiotics, and enhancing research and development (R&D) to bring new antibacterials to market, particularly for the vulnerable populations most impacted by AMR. The Global AMR R&D Hub and the World Health Organisation (WHO) presented a progress report to G7 Health and Finance Ministers in May 2022, with an update in 2023. The current report provides an annual update on the financial landscape for antibacterial innovation, tracks country-by-country progress, and outlines key actions for the coming year to support G7 policy and activities.

There has been progress across the G7 and EU over the last year and commitments have been made to strengthen AMR R&D, access and equity within the United Nations Political Declaration of the High-Level Meeting on AMR approved on the 26th September. However, the translation of commitments into action should be accelerated and coordinated to ensure impact.

Key recommendations were once again made:

  • Accelerate action and accountability – Addressing AMR and its socio-economic impacts is a priority for G7 countries, requiring accelerated action, shared priorities, targets and timelines for action.
  • Align and Enhance Financing Mechanisms for AMR R&D to reward innovation – Push incentives for AMR R&D are necessary but insufficient on their own; globally coordinated actions are needed to sustain public-private partners and implement pull incentives or other innovative financing mechanisms.
  • Prioritize Equity and Global Access – Together with prioritizing the development of new antibacterials broadening equitable access to all antibacterials is also essential.

Curious about more?

You can sign up for our newsletter here. By subscribing, you automatically provide your consent for the use of your data in accordance with our privacy policy.

This field is for validation purposes and should be left unchanged.

Latest publications

Go to all publications
Dynamic Dashboard